
CAS 863971-19-1
:Ref: IN-DA003RGK
1mg138.00€5mg201.00€10mg229.00€50mgTo inquire100mgTo inquire250mgTo inquire500mgTo inquire(S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(6-(2,5-Dioxo-2,5-Dihydro-1H-Pyrrol-1-Yl)-N-Methylhexanamido)-3-Methylbutanamido)-N,3-Dimethylbutanamido)-3-Methoxy-5-Methylheptanoyl)Pyrrolidin-2-Y
CAS:(S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(6-(2,5-Dioxo-2,5-Dihydro-1H-Pyrrol-1-Yl)-N-Methylhexanamido)-3-Methylbutanamido)-N,3-Dimethylbutanamido)-3-Methoxy-5-Methylheptanoyl)Pyrrolidin-2-YPurity:98%Molecular weight:925.16g/molMcMMAF
CAS:McMMAF is a protective group-conjugated MMAF.Formula:C49H76N6O11Purity:99.65% - >99.99%Color and Shape:SolidMolecular weight:925.16MC-MMAF
CAS:MC-MMAF is an antibody that binds to the epidermal growth factor receptor (EGFR) on tumor cells and inhibits the proliferation of tumor cells by blocking the binding of epidermal growth factor. MC-MMAF has been shown to be an effective treatment for a variety of cancers, including breast cancer, lung cancer, head and neck cancer, and colorectal cancer. It is also being studied as a potential treatment for autoimmune diseases such as rheumatoid arthritis and psoriasis. MC-MMAF has been shown to improve prognosis in patients with glomerular filtration rate (GFR) less than 30 mL/min per 1.73 m2.
Formula:C49H76N6O11Purity:Min. 95 Area-%Color and Shape:White PowderMolecular weight:925.16 g/molMafodotin
CAS:Controlled ProductApplications Mafodotin is an anticancer immunoconjugate for the diagnosis and treatment of cancer or B Cell proliferative diseases.
References Valliere-Douglass, J.F., et al.: Anal. Chem., 84, 2843 (2012); Alley, S.C., et al.: Bioconjugate. Chem., 19, 759 (2008); Doronina, S.O., et al.: Bioconjugate. Chem., 17, 114 (2006);Formula:C49H76N6O11Color and Shape:NeatMolecular weight:925.1613




